(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
25 August 2011 (25.08.2011)

PCT

(10) International Publication Number
WO 2011/101806 A1

(51) International Patent Classification:
C07D 471/04 (2006.01) *A61P 19/00* (2006.01)
A61K 31/519 (2006.01) *A61P 37/00* (2006.01)
A61P 35/00 (2006.01)

(21) International Application Number:
PCT/IB2011/050669

(22) International Filing Date:
17 February 2011 (17.02.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
00415/CHE/2010 17 February 2010 (17.02.2010) IN

(71) Applicants *(for all designated States except US)*: **DE-BIOPHARM S.A.** [CH/CH]; Forum "après-demain", Chemin Messidor 5-7, CP 5911, CH-1002 Lausanne (CH). **AURIGENE DISCOVERY TECHNOLOGIES LTD.** [IN/IN]; 39-40 KIADB Industrial Area, Electronic, City, Phase II, Hosur Road, Bangalore 560 100 (IN).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **MC ALLISTER, Andrès** [IT/CH]; Rue Emile-Yung 8, CH-1205 Genève (CH). **MURONE, Maximilien** [CH/CH]; Le Grand Chemin, CH-1066 Epalinges (CH). **SENGUPTA, Saumitra** [IN/IN]; 6/7 Central Park, Kolkata 700032 (IN). **SHETTY, Shankar Jayaram** [IN/IN]; 23 Rohini Apartment, 9th Cross, Wilson Garden, Bangalore 560027 (IN).

(74) Agent: **KATZAROV SA**; Rue des Epinettes 19, CH-1227 Geneva (CH).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:


— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

WO 2011/101806 A1

(54) Title: BICYCLIC COMPOUNDS AND THEIR USES AS DUAL C-SRC / JAK INHIBITORS



(I)

(57) Abstract: The present invention relates to substituted aromatic bicyclic compounds containing pyrimidine and pyridine rings of formula (I) having the structure as well as pharmaceutically acceptable salts thereof. The compounds of the present invention are useful as tyrosine kinase inhibitors, preferably SRC family kinases (SFKs) inhibitors, in particular as multi SFK/JAK. kinases inhibitors and even preferably as dual c-SRC/JAK kinases inhibitors, thereby inhibiting the STAT3 activation and therefore abnormal growth of particular cell types. Notably, the compounds of the present invention are useful for the treatment or inhibition of certain diseases that are the result of deregulation of STAT3.